Technical Analysis for FLXN - Flexion Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
FLXN closed down 1.44 percent on Tuesday, November 20, 2018, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
|See historical FLXN trend table...|
|Date||Alert Name||Type||% Chg|
|Nov 20||20 DMA Support||Bullish||0.00%|
|Nov 20||NR7||Range Contraction||0.00%|
|Nov 20||NR7-2||Range Contraction||0.00%|
|Nov 20||Doji - Bullish?||Reversal||0.00%|
|Nov 20||Down 3 Days in a Row||Weakness||0.00%|
|Nov 19||NR7||Range Contraction||-1.44%|
|Nov 16||Calm After Storm||Range Contraction||-6.64%|
|Nov 16||Wide Bands||Range Expansion||-6.64%|
|Nov 15||Wide Bands||Range Expansion||-9.44%|
|Nov 14||20 DMA Support||Bullish||-2.90%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Flexion Therapeutics, Inc. focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. Its lead product candidate includes FX006, an intra-articular, sustained-release triamcinolone acetonide, which has completed a Phase 2b dose-ranging clinical trial to treat moderate to severe osteoarthritis (OA) pain. The company is also developing FX007, a preclinical, small-molecule TrkA receptor antagonist to address post-operative pain; and FX005, an intra-articular, sustained-release p38 MAP kinase inhibitor, which has completed a Phase 2a clinical trial to treat end-stage OA patients. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more FLXN news...
|52 Week High||29.1|
|52 Week Low||13.36|
|200-Day Moving Average||23.0763|
|50-Day Moving Average||17.4922|
|20-Day Moving Average||15.4895|
|10-Day Moving Average||16.301|
|Average True Range||1.2145|
|Chandelier Exit (Long, 3 ATRs )||15.2865|
|Chandelier Exit (Short, 3 ATRs )||17.0035|
|Upper Bollinger Band||17.6738|
|Lower Bollinger Band||13.3052|
|Percent B (%b)||0.56|
|MACD Signal Line||-0.567|
|Market Cap||502.19 Million|
|Num Shares||31.9 Million|
|Price-to-Earnings (P/E) Ratio||-5.06|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||16.97|
|Resistance 3 (R3)||16.92||16.47||16.77|
|Resistance 2 (R2)||16.47||16.15||16.49||16.70|
|Resistance 1 (R1)||16.10||15.96||16.29||16.15||16.63|
|Support 1 (S1)||15.28||15.33||15.47||15.33||14.85|
|Support 2 (S2)||14.83||15.14||14.85||14.78|
|Support 3 (S3)||14.46||14.83||14.72|
|Support 4 (S4)||14.51|